Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 2836.

https://doi.org/10.1182/blood-2019-122969

Published: 2019

Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 237.

https://doi.org/10.1182/blood-2019-124866

Published: 2019

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Journal Articles

Identification of Circulating microRNA Signatures As Potential Noninvasive Biomarkers for Prediction to Response to Extracorporeal Photoapheresis in Patients with Graft Versus Host Disease

Raul Teruel Montoya, PhD, Oriana López-Godino, MD PhD, Nuria Garcia-Barbera, Rosa Cifuentes-Riquelme, Maria Sola, MD, Inmaculada Heras, MD PhD, Cesare Perotti, PhD MD, Vicente Vicente Garcia, MD PhD, Rocio González-Conejero, PhD, Claudia Del Fante, MD PhD, Constantino Martínez, PhD, Maria Luisa Lozano, MD PhD

Blood (2019) 134 (Supplement_1): 4466.

https://doi.org/10.1182/blood-2019-121655

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

Metabolic Syndrome Post Allogeneic STEM CELL Transplantation in Adult Patients Is NOT an Uncommon Complication. a Single Center Experience

Panayotis Kaloyannidis, Deia Awami, MD, Solaf Kanfar, MD, Zahra Abdrabalamir Alshammasi, MD, Mohammed Darweesh, MD, Enas Mutahar, MD, Ahmed Bahrani, MD, Rabab Attas, Heba Raslan, MD, John Apostolidis, MD, Khalid Ahmed Al-Anazi, MD, Hani Al Hashmi, MD

Blood (2019) 134 (Supplement_1): 5695.

https://doi.org/10.1182/blood-2019-129045

Published: 2019

Journal Articles

Impact of Socioeconomic Factors on Timeliness of First Line Chemotherapy and Survival in Patients with Active Multiple Myeloma

Thejus Jayakrishnan, MD, Veli Bakalov, MD, Rodney E Wegner, MD, Santhosh Sadashiv, MD

Blood (2019) 134 (Supplement_1): 4729.

https://doi.org/10.1182/blood-2019-129147

Published: 2019

Journal Articles

High-Dose TSLP Induces Co-Receptor Internalization and Signal Shutdown in Ph-like B-ALL with Overexpression of CRLF2

WayAnne B. Watson, Hossam Alkashgari, MD, Cornelia Stoian, PhD, Jacqueline S. Coats, Ineavely Baez, Hannah Choi, Benjamin Becerra, DrPH, Rishikesh Chavan, MD, Muhammad Omair Kamal, MD, Shadi Farzin Gohar, MD, Xianmei Meng, PhD, Sinisa Dovat, MD PhD, Kimberly J. Payne, PhD, Hoda Erjaee, DVM, PhD

Blood (2018) 132 (Supplement 1): 4024.

https://doi.org/10.1182/blood-2018-99-114336

Published: 2018

Journal Articles

Management of Cytopenias in CTLA4 Haploinsufficiency Using Abatacept and Sirolimus

Gulbu Uzel, MD, Djuro Karanovic, MD, Hua Su, PhD, Amy Rump, Anahita Agharahimi, Steven M. Holland, MD, V. Koneti Rao, MD FRCPA

Blood (2018) 132 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2018-99-120185

Published: 2018

Journal Articles

Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients: Single Institutional Experience

Reyad Dada, MD, Aisha Alharbi, MD, Ehab Mosaaf, MD

Blood (2018) 132 (Supplement 1): 5356.

https://doi.org/10.1182/blood-2018-99-110262

Published: 2018

Journal Articles

Extracorporeal Photopheresis for First Line Treatment of Acute Graft Versus Host Disease

Florent Malard, MD PhD, Simona Sestili, MD, Sandra Eder, MD, Ramdane Belhocine, Annalisa Ruggeri, MD, Giorgia Battipaglia, MD, Eolia Brissot, MD PhD, Clemence Mediavilla, MD, Remy Dulery, MD, Mohamad Mohty, MD PhD

Blood (2018) 132 (Supplement 1): 2114.

https://doi.org/10.1182/blood-2018-99-114544

Published: 2018

Journal Articles

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Robert Frank Cornell, MD, Samuel Z. Goldhaber, MD, Brian G Engelhardt, MD, Javid Moslehi, MD, Madan Jagasia, MD MS, Daryl Patton, Shelton Lacy Harrell, MSN, Robert L Hall, MSN, Houston Wyatt, PharmD, Gregory Piazza, MD

Blood (2018) 132 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2018-99-112577

Published: 2018

Journal Articles

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami S. Komrokji, MD, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, David P. Steensma

Blood (2018) 132 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2018-99-111145

Published: 2018

Journal Articles

Real-World Treatment Patterns and Associated Adverse Events Among Patients with Mantle Cell Lymphoma (MCL) in the United States

Ravi Goyal, MS, Sudeep Karve, PhD, Saurabh Nagar, James A. Kaye, MD, Anthony R. Mato, MD

Blood (2017) 130 (Supplement 1): 5650.

https://doi.org/10.1182/blood.V130.Suppl_1.5650.5650

Published: 2017

Journal Articles

Biologic for the Treatment of Ph-like B-Cell Acute Lymphoblastic Leukemia with Overexpression of CRLF2

Cornelia Stoian, Jacqueline S. Coats, Veriah Vidales, Ineavely Baez, Juliette Personius, Hannah Choi, Lawrence Liu, Evgeny Chirshev, Hossam Alkashgari, Brandon Ng, Garcia Esmeralda, Benjamin Becerra, Rishikesh Chavan, Muhammad Omair Kamal, Shadi Farzin Gohar, Sinisa Dovat, Kimberly Payne

Blood (2017) 130 (Supplement 1): 2600.

https://doi.org/10.1182/blood.V130.Suppl_1.2600.2600

Published: 2017

Journal Articles

A Whole Blood Gene Expression Signature Accurately Diagnoses Multiple Myeloma and Differentiates Patients in Remission from Those with Active and Progressive Disease

Martin Schreder, MD, Santiago Barrio Garcia, PhD, Ignat Drozdov, Ken Herrmann, MDPhD, Hermann Einsele, Mark Kidd, PhDDABCC, Irvin M Modlin, MDPhDDSc, K. Martin Kortüm, MD

Blood (2017) 130 (Supplement 1): 4344.

https://doi.org/10.1182/blood.V130.Suppl_1.4344.4344

Published: 2017

Journal Articles

Apixaban Is Safe and Effective Thromboprophylaxis in Myeloma Patients Treated with Immunomodulatory Therapy

Neill Storrar, MBBChir, Abhinav Mathur, MBChB, Peter Johnson, MD, Huw Roddie, PhD

Blood (2017) 130 (Supplement 1): 1872.

https://doi.org/10.1182/blood.V130.Suppl_1.1872.1872

Published: 2017

Journal Articles

The Application of ‘Drug-Reversible’ CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation

Nina Timberlake, Maximilian Richter, Xinxin Wang, PhD, Nicholas Cam, Yening Tan, Eric M Ostertag, Devon J Shedlock, Julian D Down

Blood (2017) 130 (Supplement 1): 1893.

https://doi.org/10.1182/blood.V130.Suppl_1.1893.1893

Published: 2017

Journal Articles

IL-17-Driven Immune Signaling in Autoimmunity and Fungal Infections

Sarah Gaffen, PhD

Blood (2017) 130 (Supplement 1): SCI-48.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-48.SCI-48

Published: 2017

Journal Articles

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Sandra Lockmer, Bjorn Ostenstad, Hans Hagberg, Harald Holte, Björn Engelbrekt Wahlin, Chloe Beate Steen, Peter de Nully Brown, MD PhD, Eva Kimby

Blood (2017) 130 (Supplement 1): 2768.

https://doi.org/10.1182/blood.V130.Suppl_1.2768.2768

Published: 2017

NARROW

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Identification of Circulating microRNA Signatures As Potential Noninvasive Biomarkers for Prediction to Response to Extracorporeal Photoapheresis in Patients with Graft Versus Host Disease

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Metabolic Syndrome Post Allogeneic STEM CELL Transplantation in Adult Patients Is NOT an Uncommon Complication. a Single Center Experience

Impact of Socioeconomic Factors on Timeliness of First Line Chemotherapy and Survival in Patients with Active Multiple Myeloma

High-Dose TSLP Induces Co-Receptor Internalization and Signal Shutdown in Ph-like B-ALL with Overexpression of CRLF2

Management of Cytopenias in CTLA4 Haploinsufficiency Using Abatacept and Sirolimus

Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients: Single Institutional Experience

Extracorporeal Photopheresis for First Line Treatment of Acute Graft Versus Host Disease

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Real-World Treatment Patterns and Associated Adverse Events Among Patients with Mantle Cell Lymphoma (MCL) in the United States

Biologic for the Treatment of Ph-like B-Cell Acute Lymphoblastic Leukemia with Overexpression of CRLF2

A Whole Blood Gene Expression Signature Accurately Diagnoses Multiple Myeloma and Differentiates Patients in Remission from Those with Active and Progressive Disease

Apixaban Is Safe and Effective Thromboprophylaxis in Myeloma Patients Treated with Immunomodulatory Therapy

The Application of ‘Drug-Reversible’ CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation

IL-17-Driven Immune Signaling in Autoimmunity and Fungal Infections

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only